Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Exelixis, Inc.
Shares of the biotech company fell sharply after reporting their cancer drug Cometriq received approval from the FDA covering only a rare form of thyroid cancer. According to analyst at JPMorgan the decision cuts the amount of eligible patients by roughly 50 percent.
Going forward ... (see research report)
Subscribe to News Feeds